Viome Life Sciences – a longevity company committed to translating scientific advancements into practical and individualized health solutions – recently announced the successful closure of its $86.5 million oversubscribed Series C funding round. The major investors include Khosla Ventures, Bold Capital, WRG Ventures, and other existing and new ones. And the funding round brings Viome’s total to $175M and will be used to support research and development and retail expansion efforts.
This funding round marked the launch of Viome’s groundbreaking Gut Intelligence Test in 200 CVS locations nationwide. And it will be the first-ever gut test available in the national retail chain, both online and in-store, underscoring the test’s strong consumer demand and the need for health optimization tools.
This funding news comes on the heels of Viome’s Oral Health Solutions announcement last month, which applied its holistic approach and proprietary RNA sequencing technology to usher in a new era of oral health with an emphasis on prevention and long-term care. And Viome’s unique perspective on health goes against a one-size-fits-all diet. It uses science to compute the optimal outcome for each consumer based on their unique human and microbial gene expressions.
Nutritional practices today do not account for our biochemical individuality and contribute to many chronic diseases’ onset and progression. Viome’s data-driven approach is highly individualized and does not rely on generic nutritional guidelines that treat all humans as similar. And utilizing AI and advanced algorithms to analyze the world’s most significant gene expression data from over 600,000 samples, Viome has developed at-home tests and custom-made health products to provide each individual with the precise nutrition their body needs. This includes a unique supplement formula for every individual, a personalized biotic blend for gut health, and personalized oral biotic lozenges for oral microbiome health.
Viome launched in 2016 and is backed by a team of world-class industry experts, translational scientists, nutritionists, researchers, doctors, and advisors focused on a single mission: to improve health by delivering scientific breakthroughs that address the root causes of chronic diseases, cancer, and aging. And Viome believes that further understanding how the microbiome interacts uniquely with every individual can empower people with insights and actionable recommendations needed to live a long and healthy life.
The Series C funding round represents a significant milestone for Viome, showcasing its position as a leader in science-backed, personalized health solutions.
KEY QUOTES:
“In a world where healthcare has often been reactive, treating symptoms and targeting diseases only after they manifest, Viome is pioneering a transformative shift by harnessing the innate power of food and nutrition. Our mission is not just to prolong life but to enrich it, enabling everyone to thrive in health and vitality. At Viome, we’re empowering our customers with an individualized nutrition strategy, cutting through the noise of temporary trends and one-size-fits-all advice. We’re on a journey to redefine aging itself, and we’re invigorated by the support of our investors and customers. Together, we’re building pathways to wellness that hold the potential to enhance the lives of billions of fellow humans across the globe.”
– Viome Founder & CEO Naveen Jain
“We made the strategic decision to invest in Viome, recognizing the groundbreaking fusion of its one-of-a-kind RNA technology with state-of-the-art AI. Coupled with an unparalleled repository of biological data, this synergy doesn’t just hint at a revolution; it marks the dawn of a new era in healthcare. The promise here is staggering: the very prevention of an epidemic wave of chronic diseases, spanning mental, metabolic, cognitive, and digestive health. Our partnership with Viome isn’t just an investment; it’s a commitment to medical innovation. We’re not merely excited; we’re inspired and resolved to continue supporting Viome as they sculpt the future with revolutionary products that will redefine the paradigms of health, from early-stage cancer diagnostics to personalized nutrition solutions that respond to the individual’s unique biological signature.”
– Robbie Schwietzer, Partner at Khosla Ventures
